Background: Cutaneous bullous mastocytosis (CBM) is a rare disease characterised by erythroderma, bullae formation on trunk, scalp and extremities which evolve to erosions.
Objective: To describe a rare variant of cutaneous mastocytosis and treatment options.
Animal: A 7-month-old Yorkshire terrier puppy with erythroderma and bullae formation.
Methods: Clinical examination (including haematological, biochemical and radiographic), skin biopsy, histopathological and immunohistochemical evaluation.
Conclusion And Clinical Relevance: The case fulfills the criteria of CBM, representing a rare entity that is reported to be associated with spontaneous regression. However, in severe cases treatment with systemic corticosteroids, H1 and H2 antihistamines, and masitinib can be performed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/vde.13074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Cyclosporine Treatment for Four Pediatric Patients With Toxic Epidermal Necrolysis That Showed No Response to High-dose Corticosteroids in Combination With Intravenous Immunoglobulin: A Case Series.
Curr Ther Res Clin Exp
December 2024
Department of Critical Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Immunosuppressive agents like cyclosporine have proven effective in some pediatric cases, although there are limited case reports considering potential risks such as secondary infections.
Objective: This study investigated the safety and efficacy of Cyclosporine A in children who did not respond to high-dose corticosteroids combined with intravenous immunoglobulin (IVIG).
Methods: We reported four pediatric patients diagnosed with toxic epidermal necrolysis (TEN) received treatment at our institution.
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.
Int J Mol Sci
December 2024
Research Laboratory of Surgery-Oncology, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal and endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune checkpoint inhibitor (ICI)-based therapies have the potential to target different pathways leading to the destruction of cancer cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, the development of different adverse effects including cutaneous adverse effects during and after the treatment with ICIs is common.
View Article and Find Full Text PDFRare delayed hypersensitivity reactions to contrast media: Severe cutaneous adverse reactions.
Eur J Radiol
December 2024
Allergy Unit, Allergo-Anaesthesia Unit, Hospital Universitario de la Cruz Roja, Madrid, Spain.
The risk of developing a severe delayed cutaneous reaction (SCAR) is very low following iodine-based contrast medium (ICM) administration and extremely low following gadolinium-based contrast agent (GBCA) administration. However, SCAR can be very severe and potentially life-threatening. It is crucial for the imaging physician to recognize danger signals: bullous skin eruption, skin erosion and detachment, mucosal involvement, systemic symptoms, and laboratory abnormalities.
View Article and Find Full Text PDFEnoxaparin-Induced Bullous Hemorrhagic Dermatosis and Enoxaparin Rechallenge: A Case Report.
J Pharm Pract
January 2025
Boston Medical Center, Boston, MA, USA.
A case of enoxaparin-induced bullous hemorrhagic dermatosis is reported. A 69-year-old male with past medical history including chronic atrial fibrillation and a re-do aortic valve replacement, anticoagulated on warfarin, received an enoxaparin bridge for a molar extraction. On day 7 after restarting enoxaparin post-procedure at a therapeutic dose of 90 mg every 12 hours, the patient noticed multiple small, dark, raised lesions on his forearm and ankle.
View Article and Find Full Text PDFA Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.
Br J Biomed Sci
January 2025
St. John's Dermatopathology Laboratory, Synnovis Analytics, St. Thomas' Hospital, London, United Kingdom.
Article Synopsis
- Skin disorders are a major global health issue, affecting millions and requiring improved understanding and treatment approaches.
- Recent advancements in molecular techniques, like PCR and next-generation sequencing, have enhanced our ability to diagnose and treat these disorders accurately and effectively.
- These technologies allow for precise identification of infectious agents, genetic mutations, and gene expression patterns, leading to personalized therapies and better management of conditions like skin cancer and infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!